The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working with Novo Nordisk in the future despite the termination of its earlier ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...